Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease

Jakob A. Østergaard,Jay C. Jha,Arpeeta Sharma,Aozhi Dai,Judy S.Y. Choi,Judy B. de Haan,Mark E. Cooper,Karin Jandeleit-Dahm,Jakob A. Østergaard,Jay C. Jha,Judy S.Y. Choi,Judy B. de Haan,Mark E. Cooper
DOI: https://doi.org/10.1042/CS20210865
2022-01-21
Clinical Science
Abstract:Activation of nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome has been reported in diabetic complications including diabetic kidney disease (DKD). However, it remains unknown if NLRP3 inhibition is renoprotective in a clinically relevant interventional approach with established DKD. We therefore examined the effect of the NLRP3-specific inhibitor MCC950 in streptozotocin-induced diabetic mice to measure the impact of NLRP3 inhibition on...
medicine, research & experimental
What problem does this paper attempt to address?